^
STRN-ALK fusion
Lung Adenocarcinoma
ensartinib
Sensitive
:
C4
Curr Oncol - 1 week - (New C4)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression
Lung Adenocarcinoma
pembrolizumab
Sensitive
:
C4
Lung Cancer - 2 weeks - (New C4)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation
Lung Adenocarcinoma
afatinib + pyrotinib
Sensitive
:
C4
Thorac Cancer - 2 weeks - (New C4)
CCDC85A-ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive
:
C4
J Cell Mol Med - 2 weeks - (New C4)
SLC8A1-ALK fusion
Lung Adenocarcinoma
ceritinib
Sensitive
:
C4
Medicine (Baltimore) - 4 weeks - (New C4)
EGFR exon 21 mutation
Lung Adenocarcinoma
dacomitinib
Sensitive
:
C4
Medicine (Baltimore) - 4 weeks - (New C4)
No biomarker
Lung Adenocarcinoma
nintedanib
Sensitive
:
A1
PD-L1 underexpression
Lung Adenocarcinoma
nivolumab + ipilimumab
Sensitive
:
A2
No biomarker
Lung Adenocarcinoma
DP
Sensitive
:
A2
No biomarker
Lung Adenocarcinoma
GC
Sensitive
:
A2
No biomarker
Lung Adenocarcinoma
cisplatin + pemetrexed
Sensitive
:
A2
EGFR mutation
Lung Adenocarcinoma
gefitinib
Sensitive
:
B
EGFR T790M
Lung Adenocarcinoma
erlotinib
Sensitive
:
B
EGFR exon 19 deletion
Lung Adenocarcinoma
gefitinib
Sensitive
:
B
EGFR mutation
Lung Adenocarcinoma
afatinib
Sensitive
:
B
EGFR exon 19 deletion
Lung Adenocarcinoma
afatinib
Sensitive
:
B
EGFR L858R
Lung Adenocarcinoma
gefitinib
Sensitive
:
B
EGFR L858R
Lung Adenocarcinoma
erlotinib
Resistant
:
B
EGFR T790M
Lung Adenocarcinoma
gefitinib
Sensitive
:
B
HER-2 exon 20 insertion + TMB-L + PD-L1 negative
Lung Adenocarcinoma
Immunotherapy
Sensitive
:
B
EGFR L858R
Lung Adenocarcinoma
afatinib
Sensitive
:
B
EGFR mutation
Lung Adenocarcinoma
bevacizumab + erlotinib
Sensitive
:
C1
PD-L1 expression
Lung Adenocarcinoma
atezolizumab
Sensitive
:
C1
MET exon 14 mutation
Lung Adenocarcinoma
tepotinib
Sensitive
:
C1
EGFR exon 19 deletion
Lung Adenocarcinoma
osimertinib
Sensitive
:
C1
BRAF V600E
Lung Adenocarcinoma
trametinib + dabrafenib
Sensitive
:
C1
ATM mutation
Lung Adenocarcinoma
olaparib
Sensitive
:
C1
EGFR T790M
Lung Adenocarcinoma
osimertinib
Resistant
:
C1
EGFR L858R
Lung Adenocarcinoma
osimertinib
Sensitive
:
C1
EGFR mutation
Lung Adenocarcinoma
erlotinib
Sensitive
:
C1
EGFR mutation
Lung Adenocarcinoma
osimertinib
Sensitive
:
C1
RET fusion
Lung Adenocarcinoma
pralsetinib
Sensitive
:
C1
ALK positive
Lung Adenocarcinoma
lorlatinib
Sensitive
:
C1
MET exon 14 mutation
Lung Adenocarcinoma
capmatinib
Sensitive
:
C1
MET exon 14 mutation
Lung Adenocarcinoma
savolitinib
Sensitive
:
C1
EGFR mutation
Lung Adenocarcinoma
bevacizumab
Sensitive
:
C2
ALK rearrangement
Lung Adenocarcinoma
crizotinib
Resistant
:
C2
EGFR T790M
Lung Adenocarcinoma
afatinib
Resistant
:
C2